sufentanil sublingual 30 mcg tablet

Phase 3Completed

1 views this week 0 watching💤 Quiet

Interest: 30/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Moderate-to-severe Acute Pain

Conditions

Moderate-to-severe Acute Pain

Trial Timeline

Oct 1, 2015 → Jul 1, 2016

NCT ID

NCT02447848

About sufentanil sublingual 30 mcg tablet

sufentanil sublingual 30 mcg tablet is a phase 3 stage product being developed by Talphera for Moderate-to-severe Acute Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT02447848. Target conditions include Moderate-to-severe Acute Pain.

What happened to similar drugs?

2 of 8 similar drugs in Moderate-to-severe Acute Pain were approved

Approved (2) Terminated (0) Active (6)

✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved

✅dupilumabSanofiApproved

🔄SHR-1314 + PlaceboJiangsu Hengrui MedicinePhase 3

🔄Indacaterol + ControlNovartisPhase 3

🔄Dupilumab + PlaceboSanofiPhase 3

🔄PonesimodVanda PharmaceuticalsPhase 3

🔄sufentanil sublingual tablet 30 mcgTalpheraPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02447848	Phase 3	Completed	Oct 1, 2015	Jul 1, 2016	Moderate-to-severe Acute Pain

Competing Products

13 competing products in Moderate-to-severe Acute Pain

See all competitors

Product	Company	Stage	Hype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacaine	Pacira Biosciences	Approved	44
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + Placebo	Sun Pharmaceutical	Phase 2/3	42
SHR-1314	Jiangsu Hengrui Medicine	Phase 1	25
SHR-1314 + Placebo	Jiangsu Hengrui Medicine	Phase 1/2	32
SHR-1314 + Placebo	Jiangsu Hengrui Medicine	Phase 3	36
Indacaterol + Control	Novartis	Phase 3	40
Deucravacitinib	Bristol Myers Squibb	Pre-clinical	33
Dupilumab + Placebo	Sanofi	Phase 3	40
dupilumab	Sanofi	Approved	43
dupilumab	Sanofi	Pre-clinical	26
Ponesimod	Vanda Pharmaceuticals	Phase 3	37
sufentanil sublingual tablet 30 mcg	Talphera	Phase 3	30
Zalviso™ 15 mcg	Talphera	Phase 3	30